1. LUTS and Sexual Dysfunction: Implications for Management of BPH
Jeroen van Moorselaar 
European Urology Supplements 
Volume 2, Issue 10, Pages (December 2003)
DOI: /j.eursup

2. Fig. 1
Change in percentage (95%CI) of men with normal function after treatment (positive change indicates an improvement).
European Urology Supplements 2003 2, 13-20DOI: ( /j.eursup )

3. Fig. 2
New cases of impotence and ejaculatory dysfunction at 7.5 months follow-up.
European Urology Supplements 2003 2, 13-20DOI: ( /j.eursup )

4. Fig. 3 Tamsulosin and alfuzosin pivotal studies in the USA.
European Urology Supplements 2003 2, 13-20DOI: ( /j.eursup )

5. Fig. 4
Changes in sexual symptom score with sustained-released alfuzosin 10mg/day for 1 year.
European Urology Supplements 2003 2, 13-20DOI: ( /j.eursup )

6. Fig. 5
Change in sexual symptom score according to LUTS severity with sustained-release alfuzosin 10mg/day for 1 year.
European Urology Supplements 2003 2, 13-20DOI: ( /j.eursup )

7. Fig. 6
Effect of α-blockers on (a) bladder neck and (b) seminal vesicle pressures in rats.
European Urology Supplements 2003 2, 13-20DOI: ( /j.eursup )

8. Fig. 7
Differential effects of α1-blockers on isolated human vas deferens contraction.
European Urology Supplements 2003 2, 13-20DOI: ( /j.eursup )